Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Springworks Therapeutics ( (SWTX) ) has provided an announcement.
SpringWorks Therapeutics announced its preliminary financial results for the fourth quarter and full year 2024, reporting U.S. net product revenue for OGSIVEO® (nirogacestat) at $61.5 million and $172.0 million respectively. The company ended 2024 with approximately $462 million in cash and expects its financial position to support operations through to profitability by early 2026. SpringWorks is advancing its robust pipeline, including securing an exclusive global license for a novel therapy targeting PP2A mutations in uterine cancer, and plans further expansions and regulatory approvals in 2025, signaling growth in its market presence and impact on patient care.
More about Springworks Therapeutics
SpringWorks Therapeutics is a commercial-stage biopharmaceutical company focused on developing precision medicines for severe rare diseases and cancer. The company offers OGSIVEO® (nirogacestat), which is approved in the United States for the treatment of progressing desmoid tumors, and is working on a diverse pipeline of targeted therapies for both solid tumors and hematological cancers.
YTD Price Performance: 19.18%
Average Trading Volume: 1,212,412
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $3.2B
See more data about SWTX stock on TipRanks’ Stock Analysis page.
